Dec 13, 2021 / 09:30PM GMT
Operator
Hello. Thank you for standing by, and welcome to Allogene Therapeutics ASH 2021 Conference Call. (Operator Instructions) Please be aware that today's conference call is being recorded.
I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Ms. Cassiano, please go ahead.
Christine Cassiano - Allogene Therapeutics, Inc. - Chief Communications Officer
Thank you, operator, and welcome to all who have joined this call. Earlier today, Allogene issued 2 press releases discussing data on our ALPHA, ALPHA2 and UNIVERSAL trials presented at this year's American Society of Hematology Annual Meeting in Atlanta. These press releases, today's webcast and corresponding slides are available on our website. We're looking forward to discussing the latest results from these programs as we progress toward our goal of making AlloCAR T therapy a reality for cancer patients.
On the call today to review the data presented at ASH are Dr. David Chang, President and Chief Executive Officer; and Dr. Rafael Amado, Executive Vice
Allogene Therapeutics Inc to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the American Society of Hematology Annual Meeting Transcript
Dec 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers